279 related articles for article (PubMed ID: 22483544)
1. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
Dabydeen DA; Jagannathan JP; Ramaiya N; Krajewski K; Schutz FA; Cho DC; Pedrosa I; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1519-24. PubMed ID: 22483544
[TBL] [Abstract][Full Text] [Related]
2. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
3. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
[TBL] [Abstract][Full Text] [Related]
4. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
White DA; Camus P; Endo M; Escudier B; Calvo E; Akaza H; Uemura H; Kpamegan E; Kay A; Robson M; Ravaud A; Motzer RJ
Am J Respir Crit Care Med; 2010 Aug; 182(3):396-403. PubMed ID: 20194812
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
[TBL] [Abstract][Full Text] [Related]
6. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
[TBL] [Abstract][Full Text] [Related]
7. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
8. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
9. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
[TBL] [Abstract][Full Text] [Related]
11. Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study.
Gluskin J; Plodkowski A; Girshman J; Sarasohn D; Viteri-Jusué A; Hayan S; Torrisi J
Clin Imaging; 2021 Mar; 71():29-33. PubMed ID: 33171363
[TBL] [Abstract][Full Text] [Related]
12. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.
Nishino M; Boswell EN; Hatabu H; Ghobrial IM; Ramaiya NH
Oncologist; 2015 Sep; 20(9):1077-83. PubMed ID: 26205737
[TBL] [Abstract][Full Text] [Related]
13. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
Nishino M; Brais LK; Brooks NV; Hatabu H; Kulke MH; Ramaiya NH
Eur J Cancer; 2016 Jan; 53():163-70. PubMed ID: 26760924
[TBL] [Abstract][Full Text] [Related]
14. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.
Lamuraglia M; Raslan S; Elaidi R; Oudard S; Escudier B; Slimane K; Penna RR; Wagner M; Lucidarme O
Eur Radiol; 2016 Jan; 26(1):278-85. PubMed ID: 25953002
[TBL] [Abstract][Full Text] [Related]
15. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
16. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.
Oudard S; Thiam R; Fournier LS; Medioni J; Lamuraglia M; Scotte F; Fabre E; Kim D; Kpamegan E; Panneerselvam A; Cuenod CA
Eur J Cancer; 2012 Jul; 48(10):1512-8. PubMed ID: 22342553
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
[TBL] [Abstract][Full Text] [Related]
19. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
20. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
